Full Spectrum CBD products maintain the full profile of the marijuana plant and in addition to CBD, contain a variety of other cannabinoids including: THC, CBDa, CBG, and CBN, as well as terpenes and other compounds such as flavonoids, proteins, phenols, sterols, and esters. Technically, full spectrum products can contain 0.3% or less THC, if they are derived from the hemp species, however, full spectrum CBD products derived from non-hemp marijuana tend to have a wider cannabinoid and terpene profile.
OK, so we know that taking it won’t get you high, but taking enough (often based on your weight), can have a calming effect. And the side effects are minimal, with some people experiencing drowsiness, nausea, or tiredness. It is unlikely to negatively impact your mood or cognitive ability, making it a seemingly safer and preferred product for many.
Get to Know the CBD Isolate, Broad, and Full Spectrum Products
Broad Spectrum cannabis products maintain the whole profile of the marijuana plant, but with the THC mostly removed.
Overall, the risks of taking CBD are very low, and the rewards can be quite promising. Still, it’s important to remember that more research is needed to understand the full effects of CBD. Your treatment is a personal choice and for many, a personal journey.
When we talk about CBD, we are typically talking about CBD products, such as topical creams and ingestible oils that are created by extracting the CBD compound from the marijuana plant. Although, some CBD products do contain small amounts of THC – which we will get to.
Studies also suggest some efficacy for cancer-related pain, migraines, and fibromyalgia, and other pain conditions. 3 However, how different species, routes of administration, and doses differ in their effect is less clear, and more research is needed.
In PPM online poll, about half of respondents said they had tried medical marijuana to help alleviate their pain and related symptoms.
Approval by the US Food and Drug Administration has, so far, been limited to synthetic or pharmaceutical-grade components of cannabis. In June 2018, the agency approved Epidiolex (GW Pharmaceuticals) — a high CBD, low THC whole-plant alcohol extract — for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients age 2 and older. FDA has also approved Marinol (AbbVie) and Syndros (Insys Therapeutics), which both contain dronabinol, or synthetic THC. Both are indicated for weight loss associated with anorexia and HIV. Marinol is also indicated for severe nausea associated with cancer chemotherapy, as is FDA-approved Cesamet (Meda Pharmaceuticals). Cesamet contains the active ingredient nabilone, which has a chemical structure similar to THC.
Strains of cannabis may come with names like Purple Diesel and Blue Sky. While the term “strain” is commonly used by dispensaries, medical cannabis users and even physicians, it’s not a term used for plant nomenclature. 9 A strain name may come from a grower, producer, processor, or dispensary. A 2018 study out of Washington state found that commercial Cannabis strains fell into three broad chemotypes (chemically distinct plants that otherwise appear indistinguishable) that were defined by the THC:CBD ratio. 10
For pain relief, he recommends a dose of 15mg THC (0.0005 oz) to 15 mg CBD. In his experience, doses of THC less than 15 mg generally don’t provide pain relief. Doses may be increased if necessary, best guided under a doctor’s orders, to achieve pain relief without unacceptable side effects.
Here’s what’s known so far about how medical marijuana and a marijuana extract called CBD (cannabidiol) might affect RA.
Journal of Medical Toxicology: “Medical Marijuana and Driving: A Review.”
Benefits for RA
Some lab testing suggests that cannabinoids may help tamp down the body’s immune response. But the studies have been limited to animals, not humans.
More than half of the states have legalized marijuana for medical use. More than a dozen other states allow limited medical uses of CBD.
Arthritis Care & Research: “Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials.”